Immunology Research Group, Institute of Medical Biology, UiT The Arctic University of Norway, Tromsø, Norway.
Centre for Medicine, Clinical Research and Integrated Care, Finnmark Hospital Trust, Hammerfest, Norway.
Transfusion. 2020 Sep;60(9):2121-2129. doi: 10.1111/trf.15944. Epub 2020 Jun 30.
Maternal anti-human leukocyte antigen (HLA) Class I is commonly detected alongside anti-human platelet antigen (HPA)-1a in fetal and neonatal alloimmune thrombocytopenia (FNAIT). Little is known regarding whether the presence of anti-HLA Class I may exert an additive effect on the risk and severity of FNAIT.
We reanalyzed samples originally collected as part of a large Norwegian screening study on FNAIT during 1995-2004. This study identified and managed 170 pregnancies where the mother was HPA-1a negative and had detectable anti-HPA-1a during pregnancy. Maternal samples from 166 of these pregnancies were rescreened for anti-HLA Class I, revealing 111 (67%) that were antibody positive. Various regression models were used to assess if and how maternal anti-HLA Class I influenced the neonatal platelet count.
Unadjusted neonatal platelet counts and the frequency of neonatal thrombocytopenia was not significantly affected by the presence of anti-HLA Class I alongside anti-HPA-1a, but results from regression analyses revealed a possible increased risk when the mother was nulliparous. These results warrant further investigation.
在胎儿和新生儿同种免疫性血小板减少症(FNAIT)中,母体抗人白细胞抗原(HLA)I 类通常与抗人血小板抗原(HPA)-1a 一起检测到。对于抗 HLA I 类的存在是否会对 FNAIT 的风险和严重程度产生附加影响,人们知之甚少。
我们重新分析了最初作为 1995-2004 年期间挪威 FNAIT 大型筛查研究一部分收集的样本。该研究确定并管理了 170 例妊娠,母亲 HPA-1a 阴性且在怀孕期间可检测到抗 HPA-1a。对这些妊娠中的 166 例母亲样本进行了抗 HLA I 类的重新筛查,发现 111 例(67%)呈抗体阳性。使用各种回归模型来评估母体抗 HLA I 类是否以及如何影响新生儿血小板计数。
抗 HLA I 类与抗 HPA-1a 一起存在时,未调整的新生儿血小板计数和新生儿血小板减少症的频率不受影响,但回归分析的结果显示,当母亲为初产妇时,风险可能会增加。这些结果需要进一步调查。